You are viewing the site in preview mode

Skip to main content
Fig. 1 | Virology Journal

Fig. 1

From: EIDD-2801 resists to infection and co-infection of SARS-CoV-2 and influenza virus

Fig. 1

Administration of EIDD-2801 effectively protects mice against lethal and non-lethal influenza virus challenge. A Schematic of the mouse pathogenesis study. BALB/C mice were orally administered EIDD-2801 at a dose of 500 mg/kg for up to 5 days following intranasal infection with H1N1-UI182 (10×MLD50) or IBV/S9-MD (1×MLD50). B Body weight change of mice infected with H1N1-UI182. C Survival curves of mice infected with H1N1-UI182. D Body weight change of mice infected with IBV/S9-MD. E-F Representative images of lung tissue are presented, with photomicrographs showing histopathological changes (scale bars = 200 μm). Hematoxylin and eosin staining (H&E) and lung index (%) in groups infected with IAV E or IBV/S9-MD F. G Western Blot analysis of influenza A virus nucleoprotein (IAV NP) and matrix protein (IAV M) expression in lung tissue homogenates from H1N1-UI182-infected mice (n = 3). H Western Blot analysis of influenza B virus nucleoprotein (IBV NP) and matrix protein (IBV M) expression in lung tissue homogenates from IBV/S9-MD-infected mice (n = 3). Band intensities were measured and the expression of β-actin or GAPDH was used as loading control. Statistically significant differences between groups were determined by the Student’s t test (*) 0.01 < P < 0.05, (***) P < 0.001, “ns” denotes no significance

Back to article page